Fullerene mediates proliferation and cardiomyogenic differentiation of adipose-derived stem cells via modulation of MAPK pathway and cardiac protein expression
Authors Hao T, Zhou J, Lü S, Yang B, Wang Y, Fang W, Jiang X, Lin Q, Li J, Wang C
Received 6 September 2015
Accepted for publication 30 November 2015
Published 18 January 2016 Volume 2016:11 Pages 269—283
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Tong Hao,1,2,* Jin Zhou,2,* Shuanghong Lü,3,* Boguang Yang,2,4 Yan Wang,2 Wancai Fang,2,4 Xiaoxia Jiang,2 Qiuxia Lin,2 Junjie Li,2 Changyong Wang1,2
1School of Life Science and Technology, Harbin Institute of Technology, Harbin, 2Department of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, 3Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 4Department of Polymer Science, Key Laboratory of Systems Bioengineering of Ministry of Education, School of Chemical Engineering and Technology, Tianjin University, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Abstract: Zero-dimensional fullerenes can modulate the biological behavior of a variety of cell lines. However, the effects and molecular mechanisms of proliferation and cardiomyogenic differentiation in brown adipose-derived stem cells (BADSCs) are still unclear. In this study, we report the initial biological effects of fullerene-C60 on BADSCs at different concentrations. Results suggest that fullerene-C60 has no cytotoxic effects on BADSCs even at a concentration of 100 µg/mL. Fullerene-C60 improves the MAPK expression level and stem cell survival, proliferation, and cardiomyogenesis. Further, we found that the fullerene-C60 modulates cardiomyogenic differentiation. Fullerene-C60 improves the expression of cardiomyocyte-specific proteins (cTnT and α-sarcomeric actinin). At elevated concentration, fullerene-C60 reduces the incidence of diminished spontaneous cardiac differentiation of BADSCs with time. At the genetic level, fullerene-C60 (5 µg/mL) also improves the expression of cTnT. In addition, fullerene-C60 promotes the formation of gap junction among cells. These findings have important implications for clinical application of fullerenes in the treatment of myocardial infarction.
Keywords: C60, BADSCs, molecular mechanisms, myocardium
Nanotechnology, the use of nanomaterials <100 nm in size, is an emerging area of regenerative medicine encompassing biomarkers discovery, cell therapy, and tissue engineering.1–3 Nanomaterials easily enter cells by direct penetration or receptor-mediated endocytosis and are translocated into different organelles, to modulate the biological behaviors of cell.4 Recently, carbon nanomaterials such as zero-dimensional (0D) fullerenes, one-dimensional (1D) carbon nanotubes (CNTs), and two-dimensional (2D) graphene have been used to recreate the specialized local microenvironment for optimal cell growth and differentiation to specific cell types.5 Fullerene-C60, first reported by Kroto et al in 1985,6 is a remarkably stable cage-like molecule measuring ~0.7 nm in diameter, facilitating passive diffusion into cells and nuclei. In addition to its structural significance, fullerene-C60 is available as a pure compound, while graphene and CNT are poorly defined material structures,7 resembling clathrin-coated vesicles in cells.8 Further, the fullerene-C60 is biocompatible and does not induce cellular apoptosis/death9 or elicit reactive-inflammatory response compared with graphite and single-walled CNT.10 In addition, fullerene-C60 can bind the hydrophobic drug, protein and/or hydrophobic regions of DNA due to the highly hydrophobic nature of the spherical structure and further modulate the cellular physiology. Recently, studies suggest that fullerene-C60 easily enter cells and the nucleus in both normal and carcinoma cells, to further modulate their biological behavior. Nishimura et al11 investigated the biological role of fullerene-C60 using mouse embryonic stem cells, and found that the uptake of fullerene-C60 occurs in a concentration-dependent fashion from 2 to 20 μg/mL. The growth rate of cells was not influenced when the concentration of fullerene-C60 was <15 μg/mL.
Mesenchymal stem cells (MSCs)-based regenerative medicine is a promising strategy for the treatment of myocardial infarction (MI).12–15 Therapeutic efficacy is limited by the low proliferative rate and cardiac differentiation efficiency in vivo.16 Previous studies suggested that brown adipose-derived stem cells (BADSCs) are an ideal source for the treatment of MI due to their high cardiomyogenic differentiation potential. MAPKs, including ERK, p38, and c-JNK, play essential roles in the regulation of BADSCs’ biological effects. The ERK MAPK plays a cytoprotective role, whereas the JNK and p38 MAPK cascades mediate pro-apoptotic or cardiomyogenic differentiation.17,18
Carbon nanomaterials modulate the biological behavior of MSCs by regulating the expression of MAPK due to their superior strength and electrical conductivity. Park et al19 found that 2D graphene regulates the cardiomyogenic differentiation of MSCs by enhancing the expression of extracellular matrix proteins and cellular FAK-Src-ERK/JNK signaling molecules. In addition, 1D CNT-based nanomaterials induce MSCs differentiation toward cardiac progenitor cells in vitro and in vivo.20,21 Our previous study showed that the CNTs can accelerate gap junction formation remarkably via activation of the β1-integrin-mediated FAK/ERK/GATA4 pathway.22 Yang et al23 found that the 0D fullerol enhances the osteogenesis of human adipose-derived stem cells. Despite these exciting findings, relatively little is known about the molecular mechanism of fullerene-C60 in proliferation and cardiomyogenic differentiation of MSCs.
In the present study, we investigated the effects of 0D fullerene-C60 on the biological behavior of BADSCs, including survival, apoptosis, proliferation, and cardiomyogenic differentiation. To this end, we focused on the regulation of ERK1/2 MAPK and p38 MAPK signal transduction pathways of BADSCs under different levels of fullerene-C60. The cardiomyogenic differentiation capacity of BADSCs in the presence of fullerene-C60 was also evaluated. The transcriptional and translational expression of cTnT/α-sarcomeric actinin in BADSCs was also investigated along with the effects of fullerene-C60 on the gap junction protein Cx-43.
Materials and methods
Isolation, cultivation, and characterization of rat BADSCs
BADSCs were acquired from interscapular adipose tissue of 60–80 g Sprague Dawley rats as previously described.24,25 Animal experimental procedures were conducted according to the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Military Medical Science (Beijing, People’s Republic of China). Briefly, isolated brown adipose tissues were washed extensively using phosphate-buffered saline (PBS; pH 7.4) to remove contaminating debris and red blood cells. These tissues were minced and digested with 0.1% collagenase IV (Sigma-Aldrich Co., St Louis, MO, USA), 0.1% dispase II (Hoffman-La Roche Ltd., Basel, Switzerland), and 0.05% trypsin (Sigma-Aldrich Co.) in serum-free medium at 37°C for 40 minutes. The enzymes were inactivated by Minimum Essential Medium Eagle Alpha Modification/10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA), and the samples were filtered to remove debris. Finally, the BADSCs were collected by centrifugation, resuspended in Minimum Essential Medium Eagle Alpha Modification/15% fetal bovine serum, and cultured at 37°C and 5% CO2. The medium was replaced every other day. Flow cytometry (BD, Franklin Lakes, NJ, USA) was used to analyze and confirm the immunophenotype of BADSCs (Figure S1). In addition, the osteogenic and adipogenic differentiation activities were measured by Von Kossa staining (Figure S2) on day 14 and Oil Red O staining on day 7 (Figure S3), respectively.
The freshly isolated BADSCs were seeded in plates at an appropriate density. At appropriate level of confluency after ~72 hours, cells were washed with PBS. Fresh complete culture medium containing fullerene (Timesnano Co., Chengdu, People’s Republic of China) at different concentrations (0, 5, 25, 50, and 100 μg/mL) was added. The medium was replaced every other day.
We added 200 μL of culture medium containing 5×103 BADSCs into 96-well tissue culture plates and incubated at 37°C and 5% CO2 for 24 hours. The medium was replaced by the culture medium containing fullerene at different concentration. Cells without fullerene treatment were used as control. On days 1, 3, 5, and 7, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5.0 mg/mL, Sigma-Aldrich Co.) was added to each well and incubated for 4 hours at 37°C. Then, the supernatant was removed, and 150 μL of DMSO was added, and the absorbance at 490 nm was recorded on a microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Acridine orange/propidium iodide staining
The survival of BADSCs after fullerene treatment was investigated with acridine orange (AO) and propidium iodide (PI) staining. On days 1, 3, 5, and 7 of culture in the fullerene suspensions, BADSCs were stained by AO (0.67 μM) and PI (75 μM) for 10 minutes, respectively, according to the manufacturer’s instructions. The cellular morphology was visualized under fluorescence microscope (Leica, Wetzlar, Germany).
Flow cytometry assay
The effects of fullerenes on apoptosis of BADSCs were assessed by Annexin V-fluorescein isothiocyanate (V-FITC; Baosai, Beijing, People’s Republic of China) and PI staining followed by analysis with flow cytometry. On day 3 after treatment with fullerenes, all the cells were collected and washed twice using cold PBS. Into each cell suspension, 10 μL of Annexin V-FITC was added and incubated for 15 minutes in the dark, followed by addition of 5 μL of PI. The proportion of apoptotic-positive cells was analyzed using fluorescence-activated cell sorter (FACScan, BD) immediately.
Cells (8×104) were seeded in 24-well plates. On days 1, 3, 5, and 7 after fullerenes treatment, cells were incubated with bromodeoxyuridine (BrdU) for 1 hour and stained with anti-BrdU antibody (Sigma-Aldrich Co.) according to the manufacturer’s instructions. After washing with PBS containing 1% Triton X-100 three times, the cells were treated with anti-rabbit Cy3 fluorescent-conjugated secondary antibodies at room temperature for 90 minutes. Cell nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI). Finally, the cells were observed under fluorescence microscope (Leica). BrdU-positive (BrdU+) cells were counted from ten randomly selected fields of three independent samples. Proliferation activity of BADSCs was defined as the percentage of BrdU+ cells relative to the total number of DAPI-positive cells. The results are presented as the mean ± standard deviation (SD).
Transmission electron microscopic observation
The ultrastructural details and internalization of BADSCs in the presence of fullerene were observed using transmission electron microscopy (TEM). Briefly, BADSCs were incubated with fullerene (50 μg/mL) for 1 day. Cells were washed with PBS and fixed with 2% glutaraldehyde and 1% osmium tetroxide for 2 hours at 4°C, and were dehydrated in a series of ethanol solution (50%, 70%, 90%, 95%, and 100%). After infiltration and embedding in epoxy resins at 60°C for 48 hours, the sections were stained with lead citrate. Finally, the ultrathin section was observed with the TEM (Philip, Technai 10) operating at 80 kV.
Immunofluorescence analyses were used to investigate the role of fullerenes in the expression of cardiac-specific antigens of BADSCs. Briefly, BADSCs were seeded on slides in 24-well culture plate. The cells were treated with fullerenes for 1, 3, and 7 days. The slides were washed and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) overnight. After permeabilization with 0.1% Triton X-100, the cells were incubated with the primary antibody against cTnT (Abcam), Cx-43 (Abcam), and α-sarcomeric actinin (Actinin, Sigma-Aldrich Co.) overnight at 4°C, respectively. After rinsing, they were treated with secondary antibodies (FITC-labeled goat anti-mouse IgG or Cy3-labeled goat anti-mouse IgG) at room temperature for 90 minutes. The cell nucleus was stained using DAPI. These samples were observed under a fluorescence microscope (Leica) and analyzed using ImageJ software (NIH, Bethesda, MD, USA).
After treatment with fullerenes at different concentrations for 1, 3, and 7 days, BADSCs were homogenized in a Laemmli sample buffer (Bio-Rad Laboratories Inc., Hercules, CA, USA) on ice. After centrifugation of the lysates at 12,000× g for 10 minutes, the supernatant was collected. The protein concentration of these extracts was measured using the BCA™ Protein Assay Kit (Thermo Scientific). Equal amounts (75 μg) of extracted proteins were loaded on a 15% sodium dodecyl sulfate-polyacrylamide gel and separated by electrophoresis, and then transferred to a polyvinyldiflouride membrane (Roche). The membrane was blocked with 5% defatted milk for 1 hour at room temperature. Next, the membrane was incubated with primary antibody for rabbit anti-Cx-43, mouse anti-α-sarcomeric actinin, mouse anti-GAPDH, ERK MAPK rabbit mAb, phospho-ERK MAPK rabbit mAb, p38 MAPK rabbit mAb, and phospho-p38 MAPK rabbit mAb overnight at 4°C, and incubated with horseradish peroxidase-coupled goat anti-mouse IgG/goat anti-rabbit IgG secondary antibodies for 1 hour at room temperature. The signals of protein bands were detected with enhanced chemiluminescence reagent (Applygen, Beijing, People’s Republic of China) on X-ray films. Band intensity was normalized with GAPDH as the endogenous control.
Real-time polymerase chain reaction
For RNA extraction, total RNA was isolated from cells using TRIpure Reagent (Roche). First-strand cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the standard procedures. The real-time polymerase chain reactions were performed in triplicate with the Fast Start Universal SYBR Green Master (ROX; Roche) and run on the Step One PLUS system (Applied Biosystems, Waltham, MA, USA). Results were obtained from three independent experiments, including a no-template control. All primers were designed by the Primer 5 software (Premier Biosoft International, Palo Alto, CA, USA), and include the following: Rat-cTnTF (ggAAgACTggAgCgAAgA), Rat-cTnTR (AAgTTgggCATgAAgAgC), Rat-GAPDHF (gCAAgTTCAAACggCACAg), and Rat-GAPDHR (gCCAgTAgACTCCACgCAT).
All data are expressed as mean ± SD. Data from the five or six groups were compared, and intergroup differences were analyzed using one-way analysis of variance with Tukey’s post hoc test. Statistical analyses were performed with Origin Pro 8 software (Originlab, Northampton, MA, USA). A value of *P<0.05 or **P<0.01 was considered statistically significant.
Results and discussion
Effects of fullerene on survival of BADSCs
Of all the carbon nanomaterials, fullerene has the longest history of research on its cytotoxicity.26 Cytotoxicity studies were performed by treating BADSCs with fullerene-C60 at different concentrations. AO/PI staining was used to investigate the survival of BADSCs in the presence of fullerene-C60, as shown in Figure 1. The cells growing under all the tested fullerene suspensions were highly viable (>90%), and the number of live cells (staining green) gradually increased with culture time. Few dead cells (staining red) were observed in all groups on day 1. Besides, a few dead cells appeared on days 3–7, especially in the 100 μg/mL group on day 7, demonstrating the time-dependent and dose-dependent effect.
Figure 1 AO/PI staining images of BADSCs after fullerene-C60 treatment within 7 days.
The presence of apoptotic cells following fullerene-C60 treatment was investigated in a fluorescence-activated cell sorter study. As shown in Figure 2, few apoptotic cells (~6.13%) were present in untreated BADSCs on day 3. As expected, the number of apoptotic cells increased after fullerene-C60 treatment. The apoptotic ratio slightly increased at enhanced fullerene-C60 levels. For example, the apoptotic percentage of BADSCs exposed to 100 μg/mL of fullerene-C60 was ~9.91%. These results were consistent with the AO/PI staining. However, the apoptotic percentage was comparatively less than that of other nanomaterials, such as nano-TiO2 (50 μg/mL, 23.47%),27 CNT (20 μg/mL, 14.4%),28 and graphene oxide (50 μg/mL, 20.4%),29 suggesting minimal damage to BADSCs.
Figure 2 Analysis of apoptotic/dead cell after treatment with fullerene-C60 on day 3 by FACS test.
Several studies reported the effect of fullerene-C60 exposure under various experimental conditions using different cell lines, with different results.30 For example, Niwa et al31 found that fullerene-C60 decreased the survival and induced micronucleus in Chinese hamster ovary cells, HeLa cells, and human embryonic kidney 293 cells in low doses and following long-term exposure. Fullerene-C60 inhibited nitric oxide production and induced a very low toxicity in human macrophage cells,10,30 with a significantly lower cytotoxicity compared with single-wall/multi-wall CNT.32 In addition, studies found a dose-dependent toxicity of fullerene-C60. Sayes et al33 believed that fullerene-C60 was cytotoxic to human dermal fibroblasts and liver carcinoma cells at the 20 ppb level but was relatively nontoxic at 0.14 ppb. Our data suggested that the fullerene-C60 had no cytotoxic effect on BADSCs, even at 100 μg/mL.
Cellular uptake of fullerene
As shown in Figure S4, fullerene-C60 was spherical. Their size was obviously larger than that of fullerene-C60 molecule (0.7 nm) owing to the aggregation of fullerene-C60 while preparing the TEM sample, which is consistent with previous report.34 The uptake pathway and cellular localization were established with TEM imaging. Unlike the untreated cells (Figure 3A), many aggregates of the fullerene-C60 nanoparticles were observed as black patches inside the cell (swallow arrow) (Figure 3B and C), which confirmed efficient transfection of fullerene-C60. Further, most of fullerene-C60 accumulation occurred inside the lysosomes. In addition, very few fullerene-C60 nanoparticles were observed between the cells (Figure 3B), indicating that the uptake ratio of fullerene-C60 for BADSCs was high. The fullerene-C60 mechanism of transmission via spontaneous membrane adsorption may be similar to that of other carbon nanomaterials,35 and the internalization entails insertion and diffusion of fullerene-C60 across cell membranes. On the other hand, a previous study suggested that lower sized carbon nanomaterials easily penetrated the cell membrane.36 Therefore, the diffusion of tiny fullerene-C60 nanoparticles (~0.7 nm) was easier inside the cells compared with other carbon nanomaterials. The detailed mechanism should be further studied.
Effects of fullerene on the proliferation behavior of BADSCs
To investigate the proliferative activity of BADSCs in the presence of different concentrations of fullerene-C60, BrdU staining was carried out on days 1, 3, and 7. As shown in Figure 4A and B, >9.5% of cells in all groups were stained by BrdU on day 1. Most BrdU+ cells can be observed until day 7, although the number decreased. Further, the proportion of BrdU+ cells in fullerene-C60 groups (>13.41%) was significantly higher than that of control (9.52%) on day 1. The proliferative activity increased with increasing fullerene-C60 concentration. The proportion of BrdU+ cells after treatment with fullerene-C60 on day 1 with 5, 25, 50, and 100 μg/mL was 10.76%±1.90%, 10.89%±0.91%, 12.84%±1.22%, and 13.41%±1.17%, respectively (Figure 4B). In addition, there were no significant differences among all groups on day 7. Notably, the percentages of BrdU+ cells decreased with the extended culture time, probably due to decreased DNA synthesis levels.37 Fullerene-C60 treatment partially improved the DNA synthesis in cells, resulting in higher cell number and proliferation.23,38
The MTT assay was conducted to measure cell proliferation and viability following exposure to fullerene-C60 for 7 days. As shown in Figure 4C, the cells proliferated constantly in all the groups. The BADSCs showed a higher growth rate within 7 days, and a much larger number of cells in the fullerene-C60 group than in the control group. The number of BADSCs after treatment with 50 μg/mL and 100 μg/mL fullerene-C60 was significantly higher than that of control group on days 5 and 7, suggesting that fullerene-C60 improved the proliferative capacity.
MAPK plays important roles in cell growth.39 In this study, we analyzed the effects of fullerene-C60 on the ERK1/2 MAPK and p38 MAPK pathways on days 1, 3, and 7 (Figure 5A). The phosphorylation of ERK1/2 (p-ERK1/2) is closely related to cell survival (anti-apoptosis) and proliferation. Our present results showed no significant differences in expression of total ERK1/2 in all the experimental groups. However, fullerene-C60 treatment increased the expression levels of phosphorylated ERK1/2 (p-ERK1/2) compared with control group (Figure 5B). Further, the expression of p-ERK1/2 was increased at higher fullerene-C60 levels except for the 100 μg/mL on days 1 and 3, which indicates that fullerene-C60 enhanced the ERK1/2 activities. In addition, fullerene-C60 improved the phosphorylation of p38 (p-p38) (Figure 5C). In a word, the fullerene-C60 entering BADSCs activates ERK1/2 and p38 signaling pathways mediating stem cell survival/proliferation, resulting in improved cell survival and proliferation (Figure 6).
Effect of fullerene on cardiomyogenic differentiation of BADSCs
Previous studies showed that BADSCs spontaneously differentiated into cardiomyocytes, although the scope for improvement in differentiation efficiency remains.13,14 Our previous study found that 1D CNT and 2D graphene-based biomaterials improved the cardiac differentiation of BADSCs.21 However, the effects of fullerene-C60 on cardiomyogenic differentiation of BADSCs are unknown. We therefore cultured BADSCs in vitro, in a medium containing fullerene-C60 for 1–7 days. Initially, most cells presented fibroblast-like appearance (Figure 7). With increased culture time, elongated morphology and contractile cells were observed in all groups, indicating that some BADSCs differentiated into cardiomyocytes. In addition, the upregulation of p38 expression is an important signal suggesting cardiomyogenic differentiation of BADSCs. Jong et al40 believe that p38 MAPK signaling facilitates the spontaneous differentiation of embryonic stem cells into cardiomyocytes during the early stage of embryonic development. The control of p38 MAPK activity represented an early switch, committing stem cells into either neurogenesis (p38 off) or cardiomyogenesis (p38 on).41–43 Therefore, fullerene-C60 modulates the cardiomyogenic differentiation of BADSCs by adjusting the expression of p38 MAPK pathway (Figure 6). In order to further investigate the effects of fullerene-C60 on cardiac differentiation efficiency of BADSCs, the expression of cardiomyocyte-specific proteins (cTnT, α-sarcomeric actinin, and Cx-43) was determined via immunofluorescence staining and Western blotting. The degree of cTnT transcription was also measured by real-time polymerase chain reaction.
Effect of fullerene-C60 on the expression of cTnT
As shown in Figure 8A, several cTnT-positive (cTnT+, green) cells were observed in all the groups on days 1, 3, and 7, indicating differentiation of a few BADSCs into cardiomyocytes. Further, we found a dose- and time-dependent cardiac differentiation of BADSCs. On day 1, the number of cTnT+ cells after treatment with fullerene-C60 was obviously higher than in control groups. The percentage of cTnT+ increased from 21.75%±6.19% to 36.40%±1.23% on day 1 when the concentration of fullerene-C60 increased from 0 to 100 μg/mL (Figure 8B), indicating the additional differentiation of BADSCs into cardiomyocytes after treatment with fullerene-C60. The electrical conductivity of fullerene-C60 may be the primary factor driving the differentiation. The percentage of cTnT+ cells increased to 38.25%±2.98% in the control group on day 3, which was higher than in the fullerene-C60 group, suggesting that BADSCs underwent spontaneous cardiomyogenic differentiation. In addition, a shuttle-like morphology of cTnT+ cells was observed on day 3 starting with the rounded shape on day 1. Further, these cells were connected with each other and showed striated patterns (inset in Figure 8A), especially in fullerene-C60 groups, which were the typical cardiomyocytes.21 On day 7, the number of cTnT+ cells was obviously reduced in the control group, indicating decrease in the capacity for spontaneous differentiation of BADSCs. Surprisingly, the number of cTnT+ cells continued to increase in the 5 μg/mL group.
The effects of fullerene-C60 on the expression of cTnT were similar to the results with immunofluorescence staining. On day 7, the expression in the experimental groups (except 100 μg/mL) was higher than that of the control group, especially at a concentration of 5 μg/mL. However, the gene expression was at odds with that of the protein levels at similar time points, consistent with the results of Gao et al,44 who found that the cTnT protein expression was upregulated between test groups and controls, without any significant differences in mRNA expression.
Effect of fullerene-C60 on the expression of α-sarcomeric actinin
The expression of the cardiac marker α-sarcomeric actinin was similar to that of cTnT, as shown in Figure 9A. The α-sarcomeric actinin-positive cells (green) were observed in all groups, especially in 50 and 100 μg/mL fullerene-C60 groups on day 3. Western blot test also suggested that the fullerene-C60 improved the expression of α-sarcomeric actinin (Figure 9B), and the expression level decreased with culture time. Further, limited α-sarcomeric actinin expression was observed in the 0–25 μg/mL group on day 7, but the cells in 50 and 100 μg/mL groups showed an elevated expression of α-sarcomeric actinin. These results suggest that the spontaneous cardiac differentiation of BADSCs decreased with time, which was prevented by high concentrations of fullerene-C60. Because fullerene-C60 can be easily taken up by BADSCs, it can further mediate cardiomyogenic differentiation via modulation of the expression of p38 pathway and cardiac protein expression.
Effect of fullerene-C60 on Cx-43 expression
The gap junction protein Cx-43, which is responsible for electrical and mechanical coupling,45 plays critical roles in cell growth and differentiation. It is the most widely expressed as well as the most representative of cardiac myocytes gap junctions, and enables cell-to-cell communication. Immunofluorescence staining showed that Cx-43 was expressed around the edges of the cells in all groups (Figure 10). Moreover, the Western blot revealed that the Cx-43 expression level in the control group was lower than in fullerene-C60 groups at all time points (Figure 9C). No statistical differences were seen among fullerene-C60 groups on day 1, while the expression level of Cx-43 increased with rising level of fullerene-C60. These results indicate that the fullerene-C60 was beneficial for the formation of gap junctions among cells and further improved the cell–cell communication (Figure 6). TEM images also showed the formation of gap junction. As shown in Figure 11, the BADSCs-derived cardiac-like cells showed more compact gap junctions at 50 μg/mL fullerene-C60 than in control group (the crude arrows). The results suggested that fullerene-C60 enhanced the cardiac differentiation of BADSCs, and promoted the maturation of cardiac-like cells, in relation to the electrical conductivity of carbon nanomaterials.
Figure 10 Immunofluorescence staining micrographs of the BADSCs cultivated in the presence of fullerene-C60 for Cx-43 and nucleus.
In summary, our findings provide evidence supporting the role of fullerene-C60 in modulating the proliferation and cardiomyogenic differentiation of rat BADSCs. The fullerene-C60 nanomaterials do not induce the cytotoxicity in BADSCs even at high concentrations (100 μg/mL). In addition, fullerene-C60 easily transfects cells and modulates the expression of MAPK signaling (ERK and p38) related to stem cell survival, proliferation, and cardiomyogenesis, thereby enhancing proliferative activity of BADSCs. Further, fullerene-C60 improves cardiomyogenic differentiation of BADSCs. It promotes the formation of gap junctions in cells and further improves the cell–cell communication. These results provide an opportunity to enhance the proliferation and cardiomyogenic differentiation of stem cells, and suggest evidence for the potential application of fullerene-C60 in the treatment of MI via cell therapy or tissue engineering.
This work was supported by the National Natural Science Funds for Distinguished Young Scholar (No 31125013), National Key Basic Research and Development Program of China (No 2011CB606206), International Cooperation and Exchanges NSFC (No 31320103914), Key Program of National Natural Science Foundation of China (No 31030032), National Natural Science Foundation of China (No 31370975, No 31200733, No 31100674, No 31370987, No 31470940), and National High Technology Research and Development Program of China (No SS2015AA020304).
The authors report no conflicts of interest in this work.
Stout DA, Webster TJ. Carbon nanotubes for stem cell control. Mater Today. 2012;15:312–318.
Ku SH, Lee M, Park CB. Carbon-based nanomaterials for tissue engineering. Adv Healthcare Mater. 2013;2:244–260.
Talukdar Y, Rashkow JT, Lalwani G, et al. The effects of graphene nanostructures on mesenchymal stem cells. Biomaterials. 2014;35:4863–4877.
Cheng LC, Jiang XM, Wang J, et al. Nano–bio effects: interaction of nanomaterials with cells. Nanoscale. 2013;5:3547–3569.
Nakanishi W, Minamia K, Shresthaa LK, et al. Bioactive nanocarbon assemblies: nanoarchitectonics and applications. Nano Today. 2014;9:378–394.
Kroto HW, Heath JR, Obrien SC, et al. C60: Buckminsterfullerene. Nature. 1985;318:162–163.
Raoof M, Mackeyev Y, Cheney MA, Wilson LJ, Curley SA. Internalization of C60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex. Biomaterials. 2012;33:2952–2960.
Grausova L, Vacik J, Vorlicek V, et al. Fullerene C60 films of continuous and micropatterned morphology as substrates for adhesion and growth of bone cells. Diam Relat Mater. 2009;18:578–586.
Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials. 2008;29:3561–3573.
Fiorito S, Serafino A, Andreola F, et al. Effects of fullerenes and single-wall carbon nanotubes on murine and human macrophages. Carbon. 2006;44:1100–1105.
Nishimura T, Kubota R, Tahara M, et al. Biological effects of fullerene C60 in mouse embryonic stem cells. Toxicol Lett. 2006;164S:S214.
Park J, Kim B, Han J, et al. Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair. ACS Nano. 2015;9:4987–4999.
Wang HB, Shi JX, Wang Y, et al. Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction. Biomaterials. 2014;35:3986–3998.
Liu ZQ, Wang HB, Wang Y, et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials. 2012;33:3093–3106.
Han J, Kim B, Shin JY, et al. Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells’ therapeutic efficacy for myocardial infarction. ACS Nano. 2015;9:2805–2819.
Psaltis PJ, Zannettino AC, Worthley SG, et al. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 2008;26:2201–2210.
Kang SJ, Kim BM, Lee YJ, et al. Titanium dioxide nanoparticles induce apoptosis through the JNK/p38-caspase-8-Bid pathway in phytohemagglutinin-stimulated human lymphocytes. Biochem Biophys Res Commun. 2009;386:682–687.
Liang X, So YH, Cui JW, et al. The low-dose ionizing radiation stimulates cell proliferation via activation of the MAPK/ERK pathway in rat cultured mesenchymal stem cells. J Radiat Res. 2011;52:380–386.
Park J, Park S, Ryu S, et al. Graphene-regulated cardiomyogenic differentiation process of mesenchymal stem cells by enhancing the expression of extracellular matrix proteins and cell signaling molecules. Adv Healthcare Mater. 2014;3:176–181.
Mooney E, Mackle JN, Blond DJP, et al. The electrical stimulation of carbon nanotubes to provide a cardiomimetic cue to MSCs. Biomaterials. 2012;33:6132–6139.
Li X, Zhou J, Liu ZQ, et al. A PNIPAAm-based thermosensitive hydrogel containing SWCNTs for stem cell transplantation in myocardial repair. Biomaterials. 2014;35:5679–5688.
Sun HY, Lü SH, Jiang XX, et al. Carbon nanotubes enhance intercalated disc assembly in cardiac myocytes via the β1-integrin-mediated signaling pathway. Biomaterials. 2015;55:84–95.
Yang Z, Li CJ, Wan Y, et al. Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells. Int J Nanomed. 2014;9:4023–4031.
Yamada Y, Wang XD, Yokoyama S, et al. Cardiac progenitor cells in brown adipose tissue repaired damaged myocardium. Biochem Biophys Res Commun. 2006;342:662–670.
Liu ZQ, Wang HB, Zhang Y, et al. Efficient isolation of cardiac stem cells from brown adipose. J Biomed Biotechnol. 2010;2010:104296.
Tokuyama H, Yamago S, Nakamura E, et al. Photoinduced biochemical activity of fullerene carboxylic acid. J Am Chem Soc. 1993;115:7918–7919.
Liu S, Xu L, Zhang T, et al. Oxidative stress and apoptosis induced by nanosized titanium dioxide in PC12 cells. Toxicology. 2010;267:172–177.
Guo YY, Zhang J, Zheng YF, et al. Cytotoxic and genotoxic effects of multi-wall carbon nanotubes on human umbilical vein endothelial cells in vitro. Mutat Res. 2011;721:184–191.
Zhang W, Yan L, Li M, et al. Deciphering the underlying mechanisms of oxidation-state dependent cytotoxicity of graphene oxide on mammalian cells. Toxicol Lett. 2015;237:61–71.
Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4:26–49.
Niwa Y, Iwai N. Genotoxicity in cell lines induced by chronic exposure to water-soluble fullerenes using micronucleus test. Environ Health Prev Med. 2006;11:292–297.
Jia G, Wang H, Yan L, et al. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol. 2005;39:1378–1383.
Sayes CM, Fortner JD, Guo W, et al. The differential cytotoxicity of water-soluble fullerenes. Nano Lett. 2004;4:1881–1887.
Lao F, Chen L, Wei Li, et al. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK related apoptosis. ACS Nano. 2009;3:3358–3368.
Lopez CF, Nielsen SO, Moore PB, et al. Understanding nature’s design for a nanosyringe. Proc Natl Acad Sci U S A. 2004;101:4431–4434.
Raffa V, Ciofani G, Nitodas S, et al. Can the properties of carbon nanotubes influence their internalization by living cells? Carbon. 2008;46:1600–1610.
Xing Y, Xiong W, Zhu L, et al. DNA damage in embryonic stem cells caused by nanodiamonds. ACS Nano. 2011;5:2376–2384.
Liu H, Yang X, Zhang Y, et al. Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell. J Orthop Res. 2012;30:1051–1057.
Chi J, Zhu Y, Fu Y, et al. Cyclosporina induces apoptosis in H9C2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways. Mol Cell Biochem. 2012;367:227–236.
De Jong AM, Maass AH, Oberdorf-Maass SU, et al. Cyclical stretch induces structural changes in atrial myocytes. J Cell Mol Med. 2013;17:743–753.
Aouadi M, Bost F, Caron L, et al. p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells. 2006;24:1399–1406.
Wu J, Kubota J, Hirayama J, et al. p38 mitogen-activated protein kinase controls a switch between cardiomyocyte and neuronal commitment of murine embryonic stem cells by activating myocyte enhancer factor 2C-dependent bone morphogenetic protein 2 transcription. Stem Cells Dev. 2010;19:1723–1734.
Barruet E, Hadadeh O, Peiretti F, et al. p38 mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells. Stem Cells Dev. 2011;20:1233–1246.
Gao Y, Connell JP, Wadhwa L, et al. Amniotic fluid-derived stem cells demonstrated cardiogenic potential in indirect co-culture with human cardiac cells. Ann Biomed Eng. 2014;42:2490–2500.
Dvir T, Levy O, Shachar M, et al. Activation of the ERK1/2 cascade via pulsatile interstitial fluid flow promotes cardiac tissue assembly. Tissue Eng. 2007;13:2185–2193.
As shown in Figure S1, the expression of CD29 and CD90 is 53.49% and 50.77% for characteristic of mesenchymal stem cells, respectively, which is consistent with previous report.1 In addition, most of the cells were negative for CD45, CD133, and CD34 (which are the hematopoietic markers and endothelial cells markers).2 These data are consistent with immunophenotypic markers of MSCs.
In order to investigate the differentiation potential of BADSCs, the isolated cells were cultured under adipogenic or osteogenic microenvironment for 7 and 14 days, respectively. As shown in Figure S2, cells cultured under osteogenic microenvironment are both positive for Alizarin Red at day 14, indicating that the BADSCs have been differentiated into osteoblast. And most cells cultured under adipogenic microenvironment are positive for Oil Red O at day 7 (Figure S3), suggesting that the BADSCs have differentiated into adipocyte.
Figure S2 Alizarin Red staining images of BADSCs cultured without (A) or with (B) osteogenic-inducing microenvironment at day 14.
Figure S3 Oil Red O staining images of BADSCs cultured without (A) or with (B) adipogenic-inducing microenvironment at day 7.
Figure S4 The TEM images of fullerene-C60 nanoparticles.
Di Felice V, De Luca A, Colorita ML, et al. Cardiac stem cell research: an elephant in the room? Anat Rec. 2009;292:449–454.
Pouly J, Bruneval P, Mandet C, et al. Cardiac stem cells in the real world. J Thorac Cardiovasc Surg. 2008;135:673–678.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]